ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BRKR Bruker Corporation

66.28
2.87 (4.53%)
Last Updated: 20:45:48
Delayed by 15 minutes
Share Name Share Symbol Market Type
Bruker Corporation NASDAQ:BRKR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.87 4.53% 66.28 66.26 66.29 66.46 63.0101 63.89 418,017 20:45:48

Düzen Selects Bruker´s MALDI Biotyper for Mass Spectrometry-based Molecular Microbial Identification

05/06/2012 2:26pm

Business Wire


Bruker (NASDAQ:BRKR)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Bruker Charts.

At the 7th National Molecular and Diagnostic Microbiology Congress in Ankara, Bruker announces an exclusive framework agreement with Düzen (www.duzen.com.tr) in the area of molecular microbial identification based on MALDI-TOF mass spectrometry. Düzen is one of the leading private diagnostic laboratory groups in Turkey, and Bruker is the leading provider of mass spectrometry-based microorganism identification solutions worldwide. Düzen Laboratories, a highly regarded clinical diagnostics company for 38 years, is the pioneer in its field in introducing new technologies into routine clinical use in Turkey. In addition, Düzen also supports government and university funded health programs, and is the contract service provider of several embassies for visa applications.

Dr. Elvan Laleli-Sahin, Member of the Board of Directors, Duzen. (Photo: Business Wire)

During an extensive evaluation study of the commercially available MALDI-TOF based microorganism identification systems, Bruker’s MALDI Biotyper solution repeatedly outperformed other systems in both its analytical performance and easy to use workflow. On this basis, Düzen decided to enter into an exclusive long-term agreement with Bruker to equip its laboratories with the market leading MALDI Biotyper system.

“We decided that the MALDI Biotyper is the most suitable system based on its smart and intelligent workflows and IT embedding features, and coupled with Bruker’s service and support network significantly reduced the challenges of implementing a new technology like MALDI-TOF into our daily routine workflow,” commented Dr. Grkem Yaman, Microbiology Specialist at Düzen.

Dr. Yaman commented further: “After successfully introducing a revolutionary species identification workflow, Bruker’s team of microbiologists are continuing to expand the horizons of MALDI-TOF microbial applications, providing us with initial ideas on how to detect particular resistance mechanisms with the MALDI Biotyper. This means that MALDI-TOF based detection of β-lactamases and carbapenemases activity is possible in less than three hours, for some enzymes even within one hour. This approach also can be applied to the analysis of positive blood cultures using Bruker’s MALDI Sepsityper kit, obtaining information both on the species and its possible resistance mechanisms within a couple of hours. This may have a significant impact on the clinical management of patients in Turkey.”

“When considering potential partners it is important for us to identify not only the most reliable partner but one that fully understands our needs and requirements. Bruker’s “Open Microbiology Concept” permits us to use and connect different technologies of our choice; this flexible approach compliments our own strategy and concepts perfectly. The philosophies of both companies fit nicely together and I am looking forward to expanding the cooperation into other regions in the future,” concluded Dr. Elvan Laleli-Sahin, Member of the Board of Directors, Düzen.

Dr. Guido Mix, Director of Microbiology at Bruker Daltonics, added: “We are very pleased that after leading the MALDI-TOF-based revolution for microbial identification, Bruker is now also leading the integration of this new molecular method into the overall microbiological workflow. Our efforts toward developing smart and straightforward workflows for the daily microbiological routine of labs are especially valued by our customers. Being able to offer very robust mass spectrometer hardware and software, and proven hands-on standard operating protocols, all backed-up by our dedicated microbiology support specialists, makes Bruker a reliable long-term partner.”

About the Bruker MALDI Biotyper

Bruker’s dedicated MALDI Biotyper solution (www.bdal.com/maldibiotyper) enables molecular identification, and taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology. Bruker’s robust MALDI Biotyper method requires minimal sample preparation efforts and offers low consumables cost per sample. The MALDI Biotyper is available in a research-use-only version, as well as in an IVD-CE version according to EU directive EC/98/79 in various European countries.

ABOUT BRUKER CORPORATION (NASDAQ: BRKR)

Bruker is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information: www.bruker.com

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50300094&lang=en

1 Year Bruker Chart

1 Year Bruker Chart

1 Month Bruker Chart

1 Month Bruker Chart